Dr James Chambers discusses handling a patient enquiry about inclisiran, including how to explain current evidence for its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CHICAGO — In adults with atherosclerotic CVD or a risk ...

The US Food and Drug Administration (FDA) has approved inclisiran (Leqvio) as an adjunct to statins for further reduction of LDL cholesterol levels, the drug's developer, Novartis, announced today.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

LISBON, Portugal — Using RNA interference to inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) synthesis lowers levels of atherogenic lipoproteins across the board, new results suggest. At ...

Longer-term follow-up of high-risk patients treated with inclisiran (Leqvio; Novartis) shows that the early reductions in LDL-cholesterol levels are sustained over several years, according to results ...

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...